The role of pharmacokinetics/pharmacodynamics in setting clinical MIC breakpoints: the EUCAST approach
Open Access
- 1 March 2012
- journal article
- review article
- Published by Elsevier BV in Clinical Microbiology & Infection
- Vol. 18 (3), E37-E45
- https://doi.org/10.1111/j.1469-0691.2011.03752.x
Abstract
No abstract availableKeywords
This publication has 32 references indexed in Scilit:
- Conserving antibiotics for the future: New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspectiveDrug Resistance Updates, 2011
- A Novel Approach to Pharmacodynamic Assessment of Antimicrobial Agents: New Insights to Dosing Regimen DesignPLoS Computational Biology, 2011
- Failure of Current Cefepime Breakpoints To Predict Clinical Outcomes of Bacteremia Caused by Gram-Negative OrganismsAntimicrobial Agents and Chemotherapy, 2007
- Concentration-Effect Relationship of Ceftazidime Explains Why the Time above the MIC Is 40 Percent for a Static Effect In VivoAntimicrobial Agents and Chemotherapy, 2007
- Antimicrobial Resistance: Pharmacokinetics‐Pharmacodynamics of Antimicrobial Therapy: It’s Not Just for Mice AnymoreClinical Infectious Diseases, 2007
- European Committee on Antimicrobial Susceptibility Testing (EUCAST) Technical Notes on antimicrobial susceptibility testingClinical Microbiology & Infection, 2006
- A retrospective analysis using Monte Carlo simulation to evaluate recommended ceftazidime dosing regimens in healthy volunteers, patients with cystic fibrosis, and patients in the intensive care unitClinical Therapeutics, 2005
- Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an updateJournal of Antimicrobial Chemotherapy, 2005
- Clinical pharmacodynamics of quinolonesInfectious Disease Clinics of North America, 2003
- European harmonization of MIC breakpoints for antimicrobial susceptibility testing of bacteriaJournal of Antimicrobial Chemotherapy, 2003